| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.IJROBP.2008.11.042 |
| P698 | PubMed publication ID | 19251380 |
| P2093 | author name string | Mark Williams | |
| Constantin T Yiannoutsos | |||
| Lech Papiez | |||
| Robert Timmerman | |||
| Achilles J Fakiris | |||
| Ronald C McGarry | |||
| Mark A Henderson | |||
| P433 | issue | 3 | |
| P921 | main subject | lung carcinoma | Q18556110 |
| non-small-cell lung carcinoma | Q3658562 | ||
| P304 | page(s) | 677-682 | |
| P577 | publication date | 2009-02-27 | |
| P1433 | published in | International Journal of Radiation Oncology Biology Physics | Q2296252 |
| P1476 | title | Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study | |
| P478 | volume | 75 |
| Q36855663 | A Technique for Generating Volumetric Cine-Magnetic Resonance Imaging |
| Q87164227 | A case of severe hemoptysis after stereotactic body radiotherapy for peripherally located stage I non-small cell lung cancer |
| Q36111869 | A decade of advances in treatment of early-stage lung cancer |
| Q37687473 | A dosimetric and treatment efficiency evaluation of stereotactic body radiation therapy for peripheral lung cancer using flattening filter free beams |
| Q41825343 | A dosimetric phantom study of dose accuracy and build-up effects using IMRT and RapidArc in stereotactic irradiation of lung tumours |
| Q57282826 | A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer |
| Q32173730 | A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) |
| Q36119520 | A review of update clinical results of carbon ion radiotherapy |
| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q57498590 | Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up |
| Q92281611 | Adoption of Stereotactic Body Radiotherapy for Stage IA Non-Small Cell Lung Cancer Across the United States |
| Q89869695 | Advanced practice: An ESTRO RTTC position paper |
| Q35200640 | Alternative to surgery in early stage NSCLC-interventional radiologic approaches |
| Q37767616 | Alternatives to surgery for early stage non-small cell lung cancer-ready for prime time? |
| Q34337294 | American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer |
| Q26823670 | Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy? |
| Q37657305 | Assessing Survival and Grading the Severity of Complications in Octogenarians Undergoing Pulmonary Lobectomy. |
| Q31152462 | Associations of Radiomic Data Extracted from Static and Respiratory-Gated CT Scans with Disease Recurrence in Lung Cancer Patients Treated with SBRT |
| Q50856489 | Automatically gated image-guided breath-hold IMRT is a fast, precise, and dosimetrically robust treatment for lung cancer patients. |
| Q36258261 | Beam's-eye-view imaging during non-coplanar lung SBRT. |
| Q92860030 | Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer |
| Q35859160 | Cardiac Exposure in the Dynamic Conformal Arc Therapy, Intensity-Modulated Radiotherapy and Volumetric Modulated Arc Therapy of Lung Cancer |
| Q27301421 | Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data? |
| Q38663392 | Clinical Outcomes of 130 Patients with Primary and Secondary Lung Tumors treated with Cyberknife Robotic Stereotactic Body Radiotherapy |
| Q35150641 | Clinical analysis of stereotactic body radiation therapy using extracranial gamma knife for patients with mainly bulky inoperable early stage non-small cell lung carcinoma |
| Q30570350 | Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases. |
| Q47103518 | Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases |
| Q49356303 | Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases |
| Q34202715 | Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size |
| Q33554464 | Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-A pilot study |
| Q34396047 | Combining targeted agents with modern radiotherapy in soft tissue sarcomas |
| Q44946517 | Commissioning and initial stereotactic ablative radiotherapy experience with Vero |
| Q34373098 | Comorbidity-adjusted survival in early stage lung cancer patients treated with hypofractionated proton therapy. |
| Q52587549 | Comparing Treatment Strategies for Stage I Small-cell lung Cancer. |
| Q47446694 | Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer. |
| Q36382039 | Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis |
| Q91323191 | Comparison of single- and five-fraction schedules of stereotactic body radiation therapy for central lung tumours: a single institution experience |
| Q38914996 | Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. |
| Q26995851 | Complications from Stereotactic Body Radiotherapy for Lung Cancer |
| Q41920328 | Computed tomography fluoroscopy-guided percutaneous (125)I seed implantation for safe, effective and real-time monitoring radiotherapy of inoperable stage T1-3N0M0 non-small-cell lung cancer |
| Q43191730 | Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy? |
| Q46123351 | Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer |
| Q28950857 | Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy |
| Q34331400 | CyberKnife for hilar lung tumors: report of clinical response and toxicity |
| Q33698367 | CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment |
| Q37468265 | Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer |
| Q33907089 | Development of a small animal model to simulate clinical stereotactic body radiotherapy-induced central and peripheral lung injuries. |
| Q36661346 | Differences in the dose-volume metrics with heterogeneity correction status and its influence on local control in stereotactic body radiation therapy for lung cancer |
| Q39837257 | Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells |
| Q37672787 | Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review |
| Q35976055 | Does Radiotherapy Have Curative Potential in Metastatic Patients? The Concept of Local Therapy in Oligometastatic Breast Cancer |
| Q36100808 | Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? |
| Q42044237 | Dosimetric Comparison of Real-Time MRI-Guided Tri-Cobalt-60 Versus Linear Accelerator-Based Stereotactic Body Radiation Therapy Lung Cancer Plans |
| Q36279626 | Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer |
| Q36550512 | Dosimetric effects of roll rotational setup errors on lung stereotactic ablative radiotherapy using volumetric modulated arc therapy |
| Q48718124 | Dosimetric evaluation of four-dimensional dose distributions of CyberKnife and volumetric-modulated arc radiotherapy in stereotactic body lung radiotherapy |
| Q28730322 | Dosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastases |
| Q35888436 | Dosimetric verification of lung cancer treatment using the CBCTs estimated from limited-angle on-board projections |
| Q35983312 | Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy |
| Q64969902 | Early stage lung cancer survival after wedge resection and stereotactic body radiation. |
| Q64081214 | Editorial on comparison between stereotactic body radiotherapy and surgery in early stage NCSLC by Scotti |
| Q47826009 | Effects of collimator angle, couch angle, and starting phase on motion-tracking dynamic conformal arc therapy (4D DCAT). |
| Q27015651 | Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice |
| Q37645201 | Emerging treatment options in the management of non-small cell lung cancer. |
| Q39025274 | Estimating 4D-CBCT from prior information and extremely limited angle projections using structural PCA and weighted free-form deformation for lung radiotherapy |
| Q58760175 | Evaluation of delivered dose to a moving target by 4D dose reconstruction in gated volumetric modulated arc therapy |
| Q48604650 | Evaluation of initial setup errors of two immobilization devices for lung stereotactic body radiation therapy (SBRT). |
| Q61450341 | Evaluation of plan quality and treatment efficiency for single-isocenter/two-lesion lung stereotactic body radiation therapy |
| Q37670422 | Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy |
| Q92144007 | FFF-VMAT for SBRT of lung lesions: Improves dose coverage at tumor-lung interface compared to flattened beams |
| Q34366580 | Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume |
| Q47142210 | Heart rate recovery and survival in patients undergoing stereotactic body radiotherapy for treatment of early-stage lung cancer |
| Q89354934 | Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy |
| Q36543330 | Hope for progress after 40 years of futility? Novel approaches in the treatment of advanced stage III and IV non-small-cell-lung cancer: Stereotactic body radiation therapy, mediastinal lymphadenectomy, and novel systemic therapy |
| Q90160118 | Hypofractionated carbon-ion radiotherapy for stage I peripheral nonsmall cell lung cancer (GUNMA0701): Prospective phase II study |
| Q41773467 | Image-guided radiation therapy: Physician's perspectives |
| Q30610005 | Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models |
| Q37382440 | Imaging in thoracic oncology: case studies from Multidisciplinary Thoracic Tumor Board: (part 2 of 2 part series). |
| Q30493924 | Imaging primary lung cancers in mice to study radiation biology. |
| Q37193638 | Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance) |
| Q91868558 | Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors |
| Q36059075 | Improving Delivery Accuracy of Stereotactic Body Radiotherapy to a Moving Tumor Using Simplified Volumetric Modulated Arc Therapy |
| Q40116176 | Influence of different treatment techniques and clinical factors over the intrafraction variation on lung stereotactic body radiotherapy. |
| Q47141026 | Institutional experience on the treatment of lung and liver lesions with stereotactic body radiotherapy and Novalis Exactrac Adaptive Gating technique |
| Q31151418 | Interpreting survival data from clinical trials of surgery versus stereotactic body radiation therapy in operable Stage I non-small cell lung cancer patients |
| Q35765777 | Intrafraction verification of gated RapidArc by using beam-level kilovoltage X-ray images |
| Q52807724 | Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET). |
| Q36174551 | Ionizing radiation induces myofibroblast differentiation via lactate dehydrogenase |
| Q27016589 | Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer? |
| Q38051243 | Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery? |
| Q38233871 | Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer? |
| Q26864983 | Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer? |
| Q37637990 | Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts |
| Q41856048 | Late tumor pseudoprogression followed by complete remission after lung stereotactic ablative radiotherapy |
| Q38705115 | Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy |
| Q84587869 | Limited resection for early-stage lung cancer |
| Q34771688 | Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy |
| Q64228382 | Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC |
| Q47149089 | Low and medium doses of hypofractionated stereotactic radiotherapy could be suboptimal for early-stage lung cancer |
| Q33805678 | Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy |
| Q38647568 | Lung Stereotactic Body Radiation Therapy. |
| Q38940816 | Lung cancer: current therapies and new targeted treatments |
| Q47121935 | Lung reirradiation with stereotactic body radiotherapy (SBRT). |
| Q47102090 | Lung stereotactic body radiotherapy using a coplanar versus a non-coplanar beam technique: a comparison of clinical outcomes |
| Q84632256 | Lung-cancer related chest events detected by periodical follow-up CT after stereotactic body radiotherapy for stage I primary lung cancer: retrospective analysis of incidence of lung-cancer related chest events and outcomes of salvage treatment |
| Q36235727 | LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective |
| Q37659318 | Marginal prescription equivalent to the isocenter prescription in lung stereotactic body radiotherapy: preliminary study for Japan Clinical Oncology Group trial (JCOG1408) |
| Q34278987 | Markerless EPID image guided dynamic multi-leaf collimator tracking for lung tumors. |
| Q48961059 | Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery |
| Q64099332 | Maximum standardized uptake value at pre-treatment PET in estimating lung cancer progression after stereotactic body radiotherapy |
| Q91792791 | Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial |
| Q35710141 | Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy |
| Q37472654 | Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study |
| Q37044288 | Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer |
| Q41888159 | Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group |
| Q92891968 | Moderately Hypofractionated Radiotherapy Alone for Stage I-IIB Non-small Cell Lung Cancer |
| Q47131451 | Mortality following single-fraction stereotactic body radiation therapy for central pulmonary oligometastasis |
| Q40656245 | Multicenter prospective study of sublobar resection for c-stage I non-small cell lung cancer patients unable to undergo lobectomy (KLSG-0801): complete republication |
| Q26740333 | Non-small cell lung cancer: current treatment and future advances |
| Q56773912 | Oligometastases revisited |
| Q37993783 | Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges |
| Q35880933 | Outcomes after Stereotactic Body Radiotherapy versus Limited Resection in Older Patients with Early-Stage Lung Cancer. |
| Q35592628 | Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer |
| Q34372246 | Outcomes of accelerated hypofractionated radiotherapy in stage i non-small-cell lung cancer. |
| Q35124684 | Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules. |
| Q42154657 | Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer-Experiences from a Single Institution |
| Q33627751 | Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. |
| Q64277127 | Phase II study of compensator-based non-coplanar intensity-modulated radiotherapy for Stage I non-small-cell lung cancer |
| Q53112046 | Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy. |
| Q46139466 | Potential for Interfraction Motion to Increase Esophageal Toxicity in Lung SBRT. |
| Q64072724 | Potential reduction of lung dose via VMAT with jaw tracking in the treatment of single-isocenter/two-lesion lung SBRT |
| Q51300392 | Practical methods for improving dose distributions in Monte Carlo-based IMRT planning of lung wall-seated tumors treated with SBRT. |
| Q56528378 | Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? |
| Q35732586 | Preliminary clinical evaluation of a 4D-CBCT estimation technique using prior information and limited-angle projections |
| Q47110081 | Preliminary comparison of the registration effect of 4D-CBCT and 3D-CBCT in image-guided radiotherapy of Stage IA non-small-cell lung cancer |
| Q57987907 | Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma |
| Q26851601 | Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients |
| Q36524133 | Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis |
| Q89996520 | Prognostic impact of solid tumor component diameter in early-stage non-small cell lung carcinoma treated with intensity-modulated fractionated radiotherapy: a retrospective analysis impact of solid tumor component diameter in NSCLC treated with IMRT |
| Q36241814 | Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy? |
| Q34404209 | Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification |
| Q30416741 | Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: Executive summary |
| Q96134636 | Radiation Exposure-Induced Changes in the Immune Cells and Immune Factors of Mice With or Without Primary Lung Tumor |
| Q92952824 | Radiation-induced tumor immunity in patients with non-small cell lung cancer |
| Q26765355 | Radio(chemo)therapy in locally advanced nonsmall cell lung cancer |
| Q38685466 | Radiobiology of stereotactic body radiation therapy (SBRT). |
| Q33787072 | Radiofrequency ablation for early-stage nonsmall cell lung cancer |
| Q36462752 | Radiofrequency ablation for lung tumors: outcomes, effects on survival, and prognostic factors |
| Q28972338 | Radiofrequency ablation of lung tumours |
| Q58707448 | Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial |
| Q57875955 | Radiothérapie en conditions stéréotaxiques des patients inopérables |
| Q34000975 | Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis. |
| Q40455887 | Reducing scan angle using adaptive prior knowledge for a limited-angle intrafraction verification (LIVE) system for conformal arc radiotherapy. |
| Q35907834 | Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection |
| Q37566614 | Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer |
| Q35200592 | SBRT in operable early stage lung cancer patients. |
| Q42384628 | SBRT versus lobectomy in stage I NSCLC: knowns, unknowns and its interpretation |
| Q89795680 | Salvage video-assisted thoracoscopic lobectomy for isolated local relapse after stereotactic body radiotherapy for early stage non-small cell lung cancer: technical aspects and perioperative management |
| Q38161371 | Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team |
| Q60917984 | Simulation of dosimetry impact of 4DCT uncertainty in 4D dose calculation for lung SBRT |
| Q37013991 | Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance |
| Q30241812 | Specific toxicity after stereotactic body radiation therapy to the central chest : A comprehensive review |
| Q91742496 | Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review |
| Q35567270 | Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma |
| Q42079167 | Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma |
| Q53062109 | Stereotactic Body Radiotherapy Versus Surgery for Medically Operable Stage I Non–Small-Cell Lung Cancer: A Markov Model–Based Decision Analysis |
| Q37784902 | Stereotactic Radiosurgery for Lung Tumors |
| Q36286591 | Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours |
| Q41112569 | Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard |
| Q84443095 | Stereotactic ablative radiotherapy for inoperable stage I NSCLC |
| Q42427013 | Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer |
| Q51721308 | Stereotactic body radiation therapy (SBRT) and respiratory gating in lung cancer: dosimetric and radiobiological considerations. |
| Q89005809 | Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC) |
| Q34010065 | Stereotactic body radiation therapy for inoperable early stage lung cancer |
| Q57177641 | Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions |
| Q55171561 | Stereotactic body radiation therapy for medically inoperable, clinically localized, urothelial carcinoma of the renal pelvis: A case report. |
| Q60912983 | Stereotactic body radiation therapy for non-small cell lung cancer: A review |
| Q34368868 | Stereotactic body radiation therapy for stage I non-small cell lung cancer: a small academic hospital experience |
| Q36555959 | Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis. |
| Q64096283 | Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications |
| Q37649474 | Stereotactic body radiation therapy: a novel treatment modality |
| Q38560967 | Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients |
| Q35646076 | Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry |
| Q53054421 | Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. |
| Q61804651 | Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer |
| Q35143839 | Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry |
| Q39044493 | Stereotactic body radiotherapy for recurrent head and neck cancer: A critical review |
| Q42033188 | Stereotactic body radiotherapy for small lung tumors in the University of Tokyo Hospital |
| Q49356651 | Stereotactic body radiotherapy for stage I non-small cell lung cancer |
| Q26781806 | Stereotactic body radiotherapy in lung cancer: an update |
| Q82084588 | Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: a multicenter study |
| Q90591596 | Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer |
| Q38175120 | Stereotactic body radiotherapy: a critical review for nonradiation oncologists |
| Q28076058 | Stereotactic body radiotherapy: current strategies and future development |
| Q38367507 | Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future? |
| Q26748296 | Surgery versus stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer: less is not more |
| Q48369218 | Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. |
| Q38409012 | Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea |
| Q64967557 | The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. |
| Q36644220 | The effect of beam arrangements and the impact of non-coplanar beams on the treatment planning of stereotactic ablative radiation therapy for early stage lung cancer |
| Q34366525 | The impact of abdominal compression on outcome in patients treated with stereotactic body radiotherapy for primary lung cancer |
| Q30425240 | The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trial. |
| Q33655601 | The impact of cine EPID image acquisition frame rate on markerless soft-tissue tracking |
| Q42934262 | The mismatch repair and base excision repair pathways: an opportunity for individualized (personalized) sensitization of cancer therapy |
| Q38227883 | The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metasta |
| Q37878852 | The role of local therapy in the management of lung and liver oligometastases. |
| Q38224998 | The role of percutaneous image-guided ablation for lung tumors |
| Q37743289 | The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient? |
| Q64120986 | The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy |
| Q90407151 | Three discipline collaborative radiation therapy (3DCRT) special debate: The single most important factor in determining the future of SBRT is immune response |
| Q36835347 | Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). |
| Q26853124 | Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy? |
| Q58584561 | Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy |
| Q38930349 | Treatment: Radiation Therapy |
| Q93369476 | Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors |
| Q43112508 | Use of FDG-PET to guide dose prescription heterogeneity in stereotactic body radiation therapy for lung cancers with volumetric modulated arc therapy: a feasibility study |
| Q40342856 | What is the current status of Stereotactic body radiotherapy for stage I non-small cell lung cancer? |
| Q38172228 | What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer |
| Q92467682 | Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate |
| Q55441727 | [Radiation pneumonitis after stereotactic body radiation therapy for early stage non-small cell lung cancer]. |
| Q55441971 | [Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer]. |
| Q53288899 | [Stereotactic body radiaton therapy for 15 patients with small lung neoplasms]. |
Search more.